Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Subscribe To Our Newsletter & Stay Updated
